Amgen 2009 Annual Report Download - page 133

AMGEN INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following tables illustrate the impact of adopting this accounting standard on our Consolidated Balance
Sheets (in millions):
December 31, 2009
Excluding
the effect
of the
accounting
standard
Effect of
the
accounting
standard
Including
the effect
of the
accounting
standard
Non-current assets:
Other assets ..................................................... $ 1,069 $ (12) $ 1,057
Non-current liabilities:
Convertible notes ................................................ 5,082 (570) 4,512
Other non-current liabilities ........................................ 2,274 214 2,488
Stockholders’ equity:
Common stock and additional paid-in capital .......................... 26,030 914 26,944
Accumulated deficit .............................................. (3,752) (570) (4,322)
December 31, 2008
As
originally
reported
Effect of
the
accounting
standard “Revised”
Non-current assets:
Other assets ..................................................... $ 1,016 $ (16) $ 1,000
Non-current liabilities:
Convertible notes ................................................ 5,081 (824) 4,257
Other non-current liabilities ........................................ 1,995 309 2,304
Stockholders’ equity:
Common stock and additional paid-in capital .......................... 25,527 914 26,441
Accumulated deficit .............................................. (5,258) (415) (5,673)
The effect of this accounting standard on “Other non-current liabilities” in the Consolidated Balance Sheets
reflects the impact of deferred taxes. In addition, the effect of this accounting standard on “Common stock and
additional paid-in capital” in the Consolidated Balance Sheets reflects, principally, the impact of the equity com-
ponent of our convertible debt partially offset by deferred taxes.
As a result of the accounting change, our common stock and additional paid-in capital as of January 1, 2007,
increased from $24.2 billion, as originally reported, to $25.2 billion and our accumulated deficit as of January 1,
2007, increased from $5.2 billion, as originally reported, to $5.4 billion after applying this accounting standard.
There was no impact resulting from this accounting change on our cash flows from operating activities, investing
activities or financing activities as reflected in the Consolidated Statements of Cash Flows.
3. Acquisitions
Dompé Biotec, S.p.A
On January 4, 2008, we completed the acquisition of Dompé Biotec, S.p.A (“Dompé”), a privately held com-
pany that marketed certain of our products in Italy. This acquisition was accounted for as a business combination.
The purchase price was approximately $168 million, which included the carrying value of our existing 49%
ownership in Dompé. The purchase price paid was allocated to the net assets acquired of approximately $63 mil-
lion, principally comprised of marketing rights to marketed products, based on their estimated fair values at the
acquisition date and the excess of the purchase price over the fair values of net assets acquired of approximately
$105 million was assigned to goodwill. There was no material gain or loss related to the reacquisition of market-
ing rights previously granted to Dompé as a result of this business combination. The results of Dompé’s
F-13